Epidemiology of patients harboring extended-spectrum beta-lactamase-producing enterobacteriaceae (ESBLE), on admission;Épidémiologie des patients porteurs d'entérobactéries sécrétrices de bêtalactamase à spectre élargi (EBLSE), à l'admission

Medecine et Maladies Infectieuses

Volumn 40, Issue 11, 2010, Pages 632-636

  Guillet, M ^a   Bille, E ^a,d   Lecuyer, H ^a,d   Taieb, F ^a   Masse, V ^a   Lanternier, F ^b,c,d   Lage Ryke, N ^a   Talbi, A ^a   Degand, N ^a,d   Lortholary, O ^b,c,d   Nassif, X ^a,d   Zahar, J R ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c Centre d'Infectiologie Necker Pasteur   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Beta Lactamase; Enterobacteria; Extended spectrum

Indexed keywords

EXTENDED SPECTRUM BETA LACTAMASE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM CARRIER; BACTERIUM ISOLATE; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; EPIDEMIOLOGICAL DATA; ESCHERICHIA COLI; FRANCE; HOSPITAL ADMISSION; HUMAN; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; NONHUMAN; PREVALENCE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TEACHING HOSPITAL;

ADULT; BETA-LACTAMASES; CARRIER STATE; CHILD; ENTEROBACTERIACEAE; HUMANS; PATIENT ADMISSION; RETROSPECTIVE STUDIES;

EID: 78649316940     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2010.04.006     Document Type: Article

References (21)

1. National nosocomial infections surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32(8):470-85.
2. DiPersio J., Deshpande L., Biedenbach D., Toleman M., Walsh T., Jones R. Evolution and dissemination of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae: epidemiology and molecular report from the Sentry antimicrobial surveillance Program (1997-2003). Diagn Microbiol Infect Dis 2005, 51(1):1-7.
3. Paterson D. Resistance in gram-negative bacteria: enterobacteriaceae. Am J Med 2006, 119(6 Suppl. 1):S20-8. [discussion S62-70].
4. Paterson D., Bonomo R. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005, 18(4):657-686.
5. Cantón R., Coque T. The CTX-M beta-lactamase pandemic. Curr Opin Microbiol 2006, 9(5):466-475.
6. Rossolini G., D'Andrea M., Mugnaioli C. The spread of CTX-M-type extended-spectrum beta-lactamases. Clin Microbiol Infect 2008, 14(Suppl. 1):33-41.
7. http://www.cclinparisnord.org/BMR/2007/Rapport_BMR2007.pdf.
8. Lucet J., Decré D., Fichelle A., Joly-Guillou M., Pernet M., Deblangy C., et al. Control of a prolonged outbreak of extended-spectrum beta-lactamase-producing enterobacteriaceae in a university hospital. Clin Infect Dis 1999, 29(6):1411-1418.
9. Valverde A., Coque T., Sánchez-Moreno M., Rollán A., Baquero F., Cantón R. Dramatic increase in prevalence of fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae during non outbreak situations in Spain. J Clin Microbiol 2004, 42(10):4769-4775.
10. Ben-Ami R., Schwaber M., Navon-Venezia S., Schwartz D., Giladi M., Chmelnitsky I., et al. Influx of extended-spectrum beta-lactamase-producing enterobacteriaceae into the hospital. Clin Infect Dis 2006, 42(7):925-934.
11. Kader A., Kumar A., Kamath K. Fecal carriage of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in patients and asymptomatic healthy individuals. Infect Control Hosp Epidemiol 2007, 28(9):1114-1116.
12. Arpin C., Quentin C., Grobost F., Cambau E., Robert J., Dubois V., et al. Nationwide survey of extended-spectrum (beta)-lactamase-producing Enterobacteriaceae in the French community setting. J Antimicrob Chemother 2009, 63(6):1205-1214.
13. Drieux L., Brossier F., Sougakoff W., Jarlier V. Phenotypic detection of extended-spectrum beta-lactamase production in Enterobacteriaceae: review and bench guide. Clin Microbiol Infect 2008, 14(Suppl. 1):90-103.
14. Colodner R., Rock W., Chazan B., Keller N., Guy N., Sakran W., et al. Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis 2004, 23(3):163-167.
15. Harris A., Kotetishvili M., Shurland S., Johnson J., Morris J., Nemoy L., et al. How important is patient-to-patient transmission in extended-spectrum beta-lactamase Escherichia coli acquisition. Am J Infect Control 2007, 35(2):97-101.
16. Calbo E., Romaní V., Xercavins M., Gómez L., Vidal C., Quintana S., et al. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases. J Antimicrob Chemother 2006, 57(4):780-783.
17. Rodríguez-Baño J., Navarro M., Romero L., Muniain M., Perea E., Pérez-Cano R., et al. Clinical and molecular epidemiology of extended-spectrum beta-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: implications for control. Clin Infect Dis 2006, 42(1):37-45.
18. Rodríguez-Baño J., Navarro M., Romero L., Muniain M., Cueto M., Gálvez J., et al. Risk-factors for emerging bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Clin Microbiol Infect 2008, 14(2):180-183.
19. Goldstein F. Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections in France Multicentre Study Group. Eur J Clin Microbiol Infect Dis 2000, 19(2):112-117.
20. Lavigne J., Marchandin H., Delmas J., Moreau J., Bouziges N., Lecaillon E., et al. CTX-M beta-lactamase-producing Escherichia coli in French hospitals: prevalence, molecular epidemiology, and risk factors. J Clin Microbiol 2007, 45(2):620-626.
21. Laupland K., Church D., Vidakovich J., Mucenski M., Pitout J. Community-onset extended-spectrum beta-lactamase (ESBL) producing Escherichia coli: importance of international travel. J Infect 2008, 57(6):441-448.